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Directional atherectomy: Combining basic 
research and intervention 
Donald C. MacLeod, MB, ChB, MRCP,” Marcel de Jong,b Victor A. Umans, MD,a 
Javier Escaned, MD,b Robert-Jan van Suylen, MD,” Patrick W. Serruys, MD, PhD,” 
and Pim J. de Feyter, MD, PhD” Rotterdam, The Netherlands 
In 1985 Simpson et al1 first described the percuta- 
neous transluminal removal of atheromatous mate- 
rial from peripheral arteries by means of a novel 
catheter system. The technique was given the term 
“directional atherectomy,” denoting the selective 
excision of obstructive luminal atheroma to distin- 
guish it from surgical endarterectomy. Initial experi- 
ence indicated that directional atherectomy could be 
performed safely and effectively and might be an at- 
tractive alternative to conventional balloon angio- 
plasty in certain circumstances.2, 3 Developments in 
the atherectomy catheter and the design of suitable 
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guiding catheters allowed the extension of the tech- 
nique to the coronary arteries in 1986.4 Recently, di- 
rectional coronary atherectomy has undergone com- 
parison with coronary balloon angioplasty in a mul- 
ticenter prospective, randomized trial, the CAVEAT 
study. After brief discussion of the technical aspects 
and clinical use of directional atherectomy, this arti- 
cle will focus on the application of atherectomy as a 
route to research. 
TECHNICAL DETAILS 
The Simpson AtheroCath (Devices for Vascular 
Intervention, Redwood City, Calif.) incorporates a 
rigid metal cylinder a short distance from the distal 
tip (Fig. 1). This cylinder is windowed longitudinally 
on one side and carries an eccentric balloon on the 
other. Within the cylinder is a cup-shaped cutter that 
can travel the length of the window; the cutter is ad- 
vanced and retracted by a hollow drive cable. The 
most distal part of the cylinder serves as a collection 
chamber. Proximally, the drive cable connects with a 
hand-held, battery-operated motor that spins at 
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Fig. 1. Simpson Atherocath. In window of cutter housing, cutter and drive cable are visible. Guide wire 
has been withdrawn. Bar scale, 1 mm. 
Fig. 2. Directional atherectomy device deployed in right coronary artery, 45O left anterior oblique projec- 
tion. Eccentric balloon is inflated with contrast, opposing cutter housing to vessel wall. Rotating cutter is 
clearly visible (arrow). 
f 2,000 rpm. To position the Atherocath, a conven- 
tional 0.014-inch guide wire is passed through the 
cable lumen and manipulated across the lesion. The 
device can then be advanced. For coronary use pre- 
shaped, nonangled guiding catheters are first intro- 
duced. On retraction of the cutter, low-pressure 
inflation of the eccentric balloon holds the window 
firmly against the selected area of atherosclerotic 
plaque. Material intruding into the window is then 
shaved off and pushed into the collection chamber by 
the advancing cutter (Fig. 2). After withdrawal of the 
device from the patient, specimens are flushed back 
into the window from where they can be extracted 
(Fig. 3). The amount of tissue retrieved varies widely 
but from peripheral lesions approaches 100 mg in 
weight5 and from coronary lesions approximately 20 
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Fig. 3. Macroscopic appearance of tissue retrieved during directional coronary atherectomy. Bar scale, 1 
mm. 
mg.51 6 The rigidity and bulk of the cutting and col- 
lection system (>5F) limits coronary use to the 
proximal and middle sections of relatively large ves- 
sels (~2.5 mm); the largest device (11F) may not be 
sufficient to allow satisfactory apposition in large pe- 
ripheral arteries. 
CLINICAL APPLICATIONS 
There is debate regarding the most appropriate 
niche for atherectomy in vascular intervention; sev- 
eral reports have focused on the therapeutic poten- 
tial of the technique in peripheral and coronary ar- 
teries.2-41 7, 8 It is proposed that atherectomy may be 
advantageous in dealing with complex lesions often 
seen in unstable angina, where conventional balloon 
angioplasty can be associated with suboptimal re- 
sults. Threatened or abrupt occlusion resulting from 
balloon-induced dissection can be managed by using 
directional atherectomy to excise the intimal flap, a 
bail-out role, but this is controversial. Originally, 
atherectomy was thought less likely to provoke 
restenosis on the basis of leaving a smoother vessel 
lumen with fewer dissections. This is probably not 
the case, but the increased initial luminal gain com- 
pared with conventional balloon angioplasty may 
better accommodate subsequent restenosis. 
RESEARCH APPLICATIONS 
Directional atherectomy has created the potential 
for new directions in both clinical and laboratory re- 
search (Fig. 4). Indeed, among the new interventional 
devices, atherectomy is unique in providing the 
means to investigate pathophysiologic phenomena 
by using human vascular tissue. First, the tissue re- 
trieved by the device can be subjected to histopatho- 
logic examination. Traditionally, the pathologic fea- 
tures of atherosclerosis in human beings have been 
studied by using material excised in the operating 
theater or autopsy suite. What directional atherec- 
tomy now offers is access to fresh vascular tissue for 
immediate fixation and examination in situations 
where precise details of the current and previous 
medical history and clinical investigations are avail- 
able. Thus histopathologic appearances can be reli- 
ably related to different clinical pictures; primary 
atherosclerosis and restenosis, stable and unstable 
angina, for example. 
Second, this tissue constitutes a source of cells for 
experimental work. Of necessity, investigations of 
mechanisms at cellular level in atherosclerosis, rest- 
enosis, and acute coronary syndromes have been 
performed in animal models to date. Studies have 
identified the vascular smooth-muscle cell as having 
a pivotal role in the response to injury of the vessel 
wall.’ Smooth-muscle cells disaggregated or cultured 
from tissue excised at atherectomy can be examined 
with electron microscopy to identify subcellular or- 
ganelles and myofibrils and with immunohistochem- 
istry or electrophoresis to identify cytoskeletal pro- 
teins such as smooth muscle cell alpha-actin, to com- 
ment on cell phenotype. The distinction between the 
contractile and synthetic phenotypes of the vascular 
smooth-muscle cell in culture is shown diagrammat- 
ically in Fig. 5. Important behavioral properties of 
the smooth-muscle cell, migration, proliferation, and 
extra-cellular matrix synthesis, can be examined in 
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Fig. 4. Directional atherectomy: possible directions of research based on basis of retrieved tissue. 
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Fig. 5. Diagrammatic representation of differences in smooth-muscle phenotype: synthetic and contrac- 
tile forms. (Adapted from Thyberg et al. Arteriosclerosis 1990;10:966.) 
vitro. Also, cultured human vascular cells may be 
used as experimental models in the assessment of 
pharmacologic agents and the investigation of ge- 
netic processes in the cell, including the effects of ge- 
netic manipulation. 
Third, tissue can be frozen pending characteriza- 
tion with molecular biologic techniques. Transcrip- 
tion, the process by which the genetic code is con- 
veyed to the synthetic apparatus of the cell, and 
translation, the interpretation of the genetic message 
and consequent production of specific proteins (Fig. 
6)) can be unravelled by using monoclonal antibodies 
to recognize protein products and Northern blotting 
or in situ hybridization with selective radiolabeled 
gene probes to identify different messenger ribonu- 
cleic acid (RNA) chains (Fig. 7). 
Histopathologic studies. A number of reports have 
been generated by this aspect of directional atherec- 
tomy. Material excised from primary atherosclerotic 
lesions in peripheral vessels bore the typical appear- 
ance of dense, fibrous plaque with occasional choles- 
terol crystals. lo Two thirds of restenotic lesions in the 
periphery displayed the characteristic feature of the 
vascular response to injury, neointimal hyperplasia, 
but this feature was also found in approximately one 
third of primary lesions. lo, ‘I Coronary artery histo- 
logic features were similar; virtually all restenotic le- 
sions revealed neointimal hyperplasia, a feature seen 
nevertheless in a third of primary lesions.6 In our own 
series neointimal hyperplasia (Fig. 8) indeed corre- 
lated significantly with prior intervention, usually 
conventional balloon angioplasty, and was detected 
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Fig. 6. Diagrammatic representation of route from genomic DNA to protein synthesis. Indicated are points 
at which different agents act to identify specific processes. 
in 20 70 of primary lesions (Table 1). The presence of 
neointimal hyperplasia in a substantial proportion of 
primary atherosclerotic lesions is consistent with the 
suggestion that spontaneous intramural injury in the 
form of plaque rupture occurs commonly, often ap- 
parently without serious clinical consequence,12 and 
confirms that the primary atherosclerotic plaque is 
far from inert. What cannot yet be drawn from the 
literature is whether or not the primary atheroscle- 
rotic plaque demonstrating this evidence of vascular 
injury can distinguish subgroups of patients with a 
different pattern of symptoms, rapid onset or cre- 
scendo angina pectoris, for example. 
Neointimal hyperplasia in plaque tissue testifies to 
recent or ongoing cellular proliferation. The prolifer- 
ative status of intimal smooth muscle cells in fresh 
tissue obtained at directional atherectomy can be 
documented by using a monoclonal antibody to a cy- 
clin, the proliferating cell nuclear antigen (PCNA), 
thus identifying cells in the S, Gi, and Gz phases of 
the cell cycle. l3 By this means a recent report con- 
firmed that low rates of proliferation do exist in pri- 
mary atherosclerotic lesions,14 in agreement with the 
histologic data regarding neointimal hyperplasia. In 
a brief series of patients undergoing directional 
atherectomy for restenosis in coronary and venous 
bypass graft stents, compared with patients receiving 
atherectomy for restenosis postballoon angioplasty, 
anti-PCNA labeling indicated that smooth-muscle 
cellular proliferation may wane within a relatively 
short period of time after coronary interventions: 47 
days after stent implantation and 14 days after bal- 
loon angioplasty.‘” 
There is continuing interest in the role of throm- 
botic mechanisms in vascular events. In peripheral 
vessels adherent or incorporated thrombus was a 
common finding in relation to primary atheroscle- 
rotic lesions but less so in relation to restenotic le- 
sions.lO, l1 Although thrombus was not commented 
on in a report of 73 coronary specimens6 a recent 
communication described the presence of thrombus 
in 18 of 19 complex coronary lesions.16 Our own 
group, examining 93 consecutive coronary atherec- 
tomy specimens, noted that the presence of organized 
thrombus within the plaque (Fig. 9) was related to 
unstable angina (Table I). The proportion of cases 
was small, lo%, but in these patients the degree of 
organization of the thrombus allows us to estimate 
with some confidence that spontaneous plaque rup- 
ture took place 7 to 10 days previously. Given accu- 
rate clinical details, the comparison of primary ath- 
erosclerotic lesions demonstrating either organized 
thrombus or neointimal hyperplasia, with lesions 
showing neither of these features, provides fresh in- 
sights into the pathophysiologic nature of the plaque 
in diverse coronary syndromes. 
The features of the tissue excised at atherectomy 
may have further bearing on subsequent clinical out- 
come. Garratt et a1.i7 examined the depth of resection 
during coronary atherectomy and related this to the 
subsequent development of restenosis; deep cuts 
were suggested to be a risk factor for restenosis in 
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Fig. 7. Diagrammatic representation of techniques of (A) Northern blotting and (6) in situ hybridization. 
venous grafts and in already restenotic lesions but 
not in primary lesions. In material from 125 periph- 
eral and 39 coronary procedures, observation of a 
highly cellular intima, identification of the internal 
elastic lamina and the presence of arterial media were 
found to be predictive of restenosis after atherecto- 
my.18 Analysis of specimens from 377 coronary ath- 
erectomies revealed that the presence of lesion throm- 
bus and incision into the adventitia were the two 
factors associated with procedural complications such 
as vessel occlusion, myocardial infarction, perfora- 
tion and distal embolization in vein graftsi 
Information can also be obtained regarding other 
forms of vascular intervention. In 33 patients under- 
going directional atherectomy for restenosis subse- 
quent to balloon angioplasty, atherectomy, or laser 
angioplasty, Waller et a1.20 noted that the histologic 
appearances were similar regardless of the initial 
technique.20 The enterprising use of directional 
atherectomy in 21 patients immediately after either 
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Fig. 8. Section of primary atherosclerotic coronary artery plaque excised at directional coronary atherec- 
tomy demonstrating neointimal hyperplasia. (hematoxylin-azofloxin stain; ~450). 
Fig. 9. Section of atherosclerotic coronary artery plaque excised at directional coronary atherectomy 
demonstrating organized thrombus (T). (hematoxylin-azofloxin stain, x400). 
Table I. Frequencies with which neointimal hyperplasia 
was found in relation to lesion type and organized throm- 
bus was found in relation to symptoms in coronary artery 
plaque tissue excised from 93 patients at directional 
atherectomy 
Primary lesion Restenosis 
Neointimal hyperplasia 14/69 (20%) 17/24 (71% ) 
p < 0.001, X2 test 
Stable angina Unstable angina 
Organized thrombus l/48 (2%) 10/45 (22%) 
p < 0.01, X2 test 
Nd:YAG (“hot-tip”), holmium:YAG, or excimer laser 
angioplasty allowed Isner et a1.21 to describe the 
pathologic effects of the three modes of laser, which 
ranged from charring several cell layers thick with 
the first to a mildly basophilic, serrated appearance, 
one cell layer deep with the last.21 Findings such as 
these may be useful when considering both the pro- 
cedural result and the longer-term outcome of laser 
thermal and photoablation and may influence 
changes in clinical practice. 
Studies using directional atherectomy are en- 
hanced by the use of quantitative angiography where 
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edge-detection analysis in particular provides useful 
information on plaque geometry in relation to both 
the effect of the procedurez2 and histopathologic 
data, Conceptually, the marriage of directional 
atherectomy and intravascular ultrasonography is 
very attractive. High-quality images of the vessel wall 
will help to assess the separate contributions of the 
three modes of action of the atherectomy device: the 
“Dotter” effect, the effect of balloon inflation, and 
the effect of the cutter. Also, examination of tissue 
retrieved may prove useful in corroborating the 
information provided by intravascular ultrasonogra- 
phy with regard to the components and architecture 
of the vessel wall. In a similar manner, different types 
of thrombus, or features of the plaque such as fissur- 
ing, revealed by angioscopy, can be sought in atherec- 
tomy samples. 
Cell and cell culture studies. Bauriedel et a1.23 were 
the first to embark on cell-based investigations with 
atherectomy material and demonstrated that cells 
disaggregated from atherectomy specimens could be 
identified as smooth-muscle cells by their staining 
with monoclonal antibodies to smooth-muscle cell 
alpha-actin. 23 An extension to this work included 
electron microscopic and electrophoretic studies of 
peripheral arterial atherosclerotic material.24 The 
mixed phenotype of the intimal smooth-muscle cells 
(Fig. 5), revealed by the presence of peripheral my- 
ofilaments together with dense perinuclear or- 
ganelles, was consistent with the findings of studies 
of vascular injury in experimental animal models, 
and the distribution of cytoskeletal proteins, pre- 
dominantly beta-, alpha- and gamma-actin and vi- 
mentin was similar to that found in studies of surgi- 
cally excised human tissue. Immunofluorescence mi- 
croscopy applied to sections of tissue obtained from 
coronary arteries at atherectomy revealed that vi- 
mentin-positive smooth-muscle cells of synthetic 
phenotype were also positive for cytokeratins 8 and 
18.25 Cytokeratins are proteins found in fetal and 
neonatal but not adult vascular smooth-muscle cells, 
indicating that a subset of the coronary lesion smooth- 
muscle cells in this study had the characteristics of 
immature, dedifferentiated cells commonly associ- 
ated with proliferative properties. 
The material obtained at directional atherectomy 
can be exploited by using the technique of cell culture 
in the further use and investigation of the small 
pieces of tissue retrieved. Bauriedel et a1.23 were also 
the first to describe the cultivation of fibroblast-like 
cells from atherectomy tissue explants.23 It was sub- 
sequently reported that cells isolated from primary 
atherosclerotic and restenosing lesions in both pe- 
ripheral and coronary arteries behaved differently in 
Table II. Migratory velocity of smooth-muscle cells cul- 
tured from primary and restenotic coronary and peripheral 
arterial lesions excised at directional atherectomy 
Cell source Migratory velocity 
Primary 
Coronary 
Peripheral 
Restenotic 
Coronary 
Peripheral 
19.4 t 5.1 (n = 7) 
21.1 k 2.5 (n = 12) 
46.2 t 3.6 (n = 5) 
48.0 + 3.0 (n = 6) 
Values are expressed as mean + SEM. Units are pm/h (adapted from 
Bauriedel G, et al. Circulation 1992;85:554-64). 
initial cell culture and early subculture.26, 27 Reste- 
nosis cells demonstrated more rapid growth, attrib- 
uted to a significant subpopulation of small, low-ad- 
hesive proliferative cells that featured less among the 
cells of primary atherosclerotic origin. Two other 
findings were of particular interest. First, primary 
cells in culture did not respond to platelet-derived 
growth factor (PDGF), whereas restenosis cells re- 
sponded by increasing their growth. Second, primary 
lesion cells proliferated in response to medium con- 
ditioned by restenosis cells, allowing the authors to 
propose an autocrine growth-promoting (non-PDGF) 
function of smooth-muscle cells in restenosis lesions 
in human beings, a mechanism previously suggested 
in animal studies. In a more recent study, this group 
describes their examination of cells cultivated from 
peripheral and coronary primary atherosclerotic and 
restenotic lesions by using a computer-assisted cell 
motion analysis system.5 Cell outgrowth was not re- 
lated to any clinical parameter, including the type of 
lesion, but restenosis cells were found to display in- 
creased migratory activity during initial outgrowth in 
culture (Table II), which in conjunction with their 
earlier findings regarding proliferation, led the au- 
thors to emphasize the importance of these aspects of 
cell behavior in the restenosis process. 
Our own group has also sought to use initial and 
extended cell culture as a means of examining the 
behavior of human coronary smooth-muscle cells ob- 
tained at directional atherectomy. Confluent cells 
cultured from retrieved tissue and electron micro- 
graphic images of these cells reveal appearances con- 
sistent with a mixed contractile/synthetic phenotype 
(Fig. 10). In agreement with the report of Dartsch et 
a1.26 with respect to peripheral vascular lesions, we 
found that smooth-muscle cells cultured from rest- 
enotic coronary lesions demonstrated accelerated 
growth compared with cells from primary atheroscle- 
rotic coronary lesions that had a growth pattern sim- 
ilar to young control human umbilical artery medial 
1756 MacLeod et al. 
June 1993 
American Heart Journal 
Fig. 10. A, Confluent cultured cells derived from tissue retrieved at directional coronary atherectomy; 
typical “hill-and-valley” culture morphologic features. Electron microscopic features of smooth-muscle 
cells from coronary artery atherosclerotic plaque tissue excised at directional atherectomy. 8, peripheral 
myofibrils (m). C, perinuclear (N) organelles, endoplasmic reticulum (e), golgi bodies (g), and numerous 
ribosomes are visible. 
cells (Fig. 11). Although we were also unable to relate 
growth in culture to any clinical parameter, a factor 
favoring successful initial smooth-muscle cell out- 
growth was the presence of organized thrombus in 
the atherectomy specimen (Table III), hinting at 
links between complex lesions, unstable angina, and 
restenosis. Further, coronary cells derived from both 
types of lesion demonstrated increased extracellular 
matrix production compared with the umbilical ar- 
tery cells27 (Table IV), consistent with the concept 
that extracellular matrix synthesis is a property of 
the adult vascular smooth-muscle cell important in 
both primary atherosclerosis and restenosis. 
Cultured human vascular cells provide us with new 
alternative experimental models for the assessment 
of the in vitro actions of existing therapies and, po- 
tentially, for the development of novel treatment 
strategies. Having previously noted that material re- 
trieved from patients receiving angiotensin-convert- 
ing enzyme inhibitors was less likely to demonstrate 
successful smooth-muscle cell outgrowth,2g Bauriedel 
et a1.30 showed recently by means of cell motion 
analysis and cell population doubling times that two 
aspects of smooth-muscle cell growth in culture, mi- 
gration, and proliferation responded similarly but to 
different extents to a variety of exogenous pharma- 
cologic agents. The combination of photosensitizing 
hematoporphyrin derivatives and photoradiation, a 
potential means of localizing and attacking the ath- 
erosclerotic plaque, has been examined by using 
smooth-muscle cells cultured from tissue retrieved 
during peripheral arterial atherectomy.31 These cells 
were found to be more susceptible to damage than 
control vascular smooth-muscle cells cultured from 
healthy arteries biopsied postmortem. Cell-culture 
models need not be restricted to monolayers of one 
particular cell type. Coculture systems, as recently 
reviewed by Betz,32 can be constructed to mimic the 
vessel wall and thus cater for important interactions 
such as those that occur between the endothelium 
and the media. 
“Gene therapy”,33 whereby new genetic material is 
introduced to the cell by using methods such as lipo- 
fection,34 retroviral vectors,35 engineered cells,36, 37 
and even particle bombardment,38 is a source of con- 
siderable current interest. Cells in culture may be 
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Table ill. Frequency of smooth-muscle cell outgr,owth in 98 
attempted cultures in relation to presence of organized 
thrombus in coronary artery plaque tissue excised at 
directional atherectomy 
SMC outgrowth 
Thrombus No thrombus 
8/10 (80%) 35/88 (40 % ) 
p < 0.025, X2 test 
Table IV. Extracellular matrix production of collagen and 
sulphated-glycosaminoglycans of human coronary cells 
cultured from plaque tissue excised at directional atherec- 
tomy and of smooth muscle cells cultured from media of 
human umbilical arteries 
Cell source Collagen Glycosaminoglycans 
Restenosis 0.034 + 0.006l 11.5 * 1.13 
Primary 0.033 * 0.0042 15.4 k 3.14 
Umbilical 0.019 * 0.0041~2 5.4 t 1.03,4 
Collagen synthesis was determined by the uptake of tritiated proline and 
sulphated-glycosaminoglycan synthesis by the incorporation of 35 sulphate. 
Values are nanomols of ligand per microgram of total protein, mean + SEM; 
L3 p < 0.05, *p < 0.005. 
used to evaluate the success and effects of attempts 
to modify the genome and influence translation and 
transcription; human vascular cells obtained at 
atherectomy are a logical preliminary testing ground. 
Frozen tissue studies. The recent publication of 
Leclerc et a1.3g focuses on transcription (Fig. 6) and 
reports the increased expression of messenger RNA 
for nonmuscle myosin heavy chain-B (MHC-B) in 
the intimal smooth-muscle cells of restenosis tissue 
compared with primary atherosclerotic tissue re- 
trieved at peripheral or coronary atherectomy.3g This 
finding is of interest because nonmuscle myosin has 
been implicated in vascular smooth-muscle cell divi- 
sion and proliferation; the method is a timely re- 
minder of the application of molecular biologic tech- 
niques in clinical science. The mRNA for MHC-B 
was detected by in situ hybridization (Fig. 7) by us- 
ing an antisense complementary (c)RNA probe pre- 
pared from recently cloned complementary deoxyni- 
bonucleic acid (DNA) coding for an isoform of the 
human nonmuscle MHC-B gene. To control for the 
specificity of the antisense cRNA probe, parallel hy- 
bridizations were performed with the sense cRNA 
probe; to control for cross-hybridization of the non- 
muscle myosin probe to smooth-muscle myosin, hy- 
bridizations were performed in normal human inter- 
nal mammary artery media preparations. By using a 
similar technique, this research group has now in- 
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Fig. 11. Growth curves of smooth-muscle cells derived 
from human coronary restenotic and primary atheroscle- 
rotic lesions and from normal human umbilical artery me- 
dia in secondary culture. 
vestigated the possible role of transforming growth 
factor-p (TGF-P) and suggests that it may be in- 
volved in vascular restenosis.40 Work of this nature, 
probing genetic regulation in plaque tissue, has par- 
ticular relevance in view of the possibilities of gene 
therapy. However, on a note of caution, as the num- 
ber of growth factors and other mediators implicated 
in atherogenesis and restenosis expands the dith- 
culty of interpreting this newfound knowledge of the 
cell renders the choice of optimal targets less straight- 
forward. 
PROSPECTS 
The various research techniques we have men- 
tioned are unlikely to excite the cell biologist, who is 
well acquainted with them. However, with the advent 
of directional atherectomy, it is now possible to ap- 
ply such techniques in a systematic manner to the 
investigation of atherosclerosis, our most common 
source of mortality, and restenosis, the response to 
injury that besets vascular intervention, by using 
human material. The identification of pathophysio- 
logic mechanisms within the cell holds out the pros- 
pect of discovering, developing, and testing new 
pharmacologic or genetic therapies that can then be 
assessed in human cell culture systems. Work of this 
nature represents an important advance at a time 
when, in the field of restenosis, the failure of both 
empiric drug trials and trials based on apparently 
sound animal experimental evidence is a cause of 
concern.41, 42 Directional atherectomy opens up new 
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avenues of research, but it falls to the intervention- 
alist to generate the enthusiasm among colleagues in 
the basic sciences that is the stimulus for fresh col- 
laborative research. 
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